Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $89.7 million.

  • Ligand Pharmaceuticals' Other Operating Expenses fell 40.25% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of $89.7 million for FY2024, which is 4127.25% up from last year.
  • As of FY2024, Ligand Pharmaceuticals' Other Operating Expenses stood at $89.7 million, which was up 4,127.25% from $2.1 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Other Operating Expenses registered a high of $89.7 million during FY2024, and its lowest value of -$600,000 during FY2020.
  • Moreover, its 3-year median value for Other Operating Expenses was $87.1 million (2022), whereas its average is $59.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Other Operating Expenses slumped by 100.07% in 2020, and later spiked by 6,366.67% in 2021.
  • Ligand Pharmaceuticals' Other Operating Expenses (Yearly) stood at -$600,000 in 2020, then soared by 6,366.67% to $37.6 million in 2021, then skyrocketed by 131.55% to $87.1 million in 2022, then tumbled by 97.56% to $2.1 million in 2023, then spiked by 4,127.25% to $89.7 million in 2024.